Tuesday, 18 Dec 2018

You are here

Type I Interferon Drives Photosensitivity in Cutaneous Lupus

Kahlenberg and coworkers have reported in ARD that interferon kappa (IFN-κ) is a key regulator of type I interferon (IFN) photosensitive responses in patients with cutaneous lupus erythematosus (CLE).

They analyzed mRNA expression of type I IFN gene expression by microarrays of biopsied CLE lesions and healthy control skin. They also examined gene expression in cultured keratinocytes, fibroblasts and endothelial cells IFNK knock-out keratinocytes generated using CRISPR/Cas9. 

They discovered that IFNK is one of two type I IFNs significantly increased (1.5-fold change) in lesional CLE skin.

Type I IFN responses were enriched in keratinocytes, but not in fibroblast or endothelial cells, and that epithelial-derived IFN-κ is responsible for maintaining baseline type I IFN responses in healthy skin.

Increased levels of IFN-κ seen in SLE can amplify and accelerate responsiveness of epithelia to IFN-α and increase keratinocyte sensitivity to UV irradiation.

IFN-κ is a critical IFN in CLE pathology via promotion of enhanced IFN responses and photosensitivity and could therefore be a potential novel treatment target.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Genetic Diagnosis for Previously Undiagnosed Disorders

The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders. The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the evaluation of the most challenging cases and to identify the biologic characteristics of newly discovered diseases.

SLE and Risk of Malignancy

The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied.  A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma. 

The Benefits of a Lupus Clinic

A comparative cohort study assessing the quality of care in patients with systemic lupus erythematosus (SLE) suggests that a dedicated lupus clinic has better quality measure performance compared to lupus management in a general rheumatology clinic.

A study from Rush University enrolled 150 consecutive SLE patients - with 73 followed in the general rheumatology clinic and 77 followed in a dedicated lupus clinic. 

Diagnosing Early Lupus from Mimics

A multicenter study of early systemic lupus erythematosus (SLE) patients examined manifestations at disease onset and found that certain clinical features can help to distinguish early SLE from other SLE‐mimicking conditions. 

High CV Risk in Lupus

Patients with systemic lupus erythematosus (SLE) remain at risk for accelerated atherosclerosis, and important questions have yet to be answered, British investigators reported.